337 / 1708
Medulloblastoma European Consensus 2015
•
CONCENSUS Day 1:
•
All tumours subtyped by 450 K array or validated method - preferably 2 techniques as part of initial
clinical workup
•
Neurosurgeons should aim for maximal safe removal: NTR (to be defined) is acceptable and
prognostically equivalent to GTR for staging
•
QOL short, medium and long term is a high priority and should be evaluated in all patients
•
Reduced CSI RTX for STR/NTR + M0; re evaluate 1.5 cm
2
residual as high risk criterion
•
All wnt properly subtyped < 16 years old have excellent prognosis and should be treated with
reduced radiation/chemotherapy
•
SHH + TP53 mutation = very poor prognosis: new treatment options needed especially if germline
TP53 mutation
•
Every SHH patient/family should be offered genetic counselling
•
All SHH tumours should be sequenced for somatic and germline mutations of TP53, PTCH, SUFU as
part of the diagnostic process
•
Recurrent tumours should be rebiopsied before using targeted therapy or 2 years beyond initial
diagnosis or diagnosis is in doubt
•
Central review of MRI scans, pathology and radiotherapy planning in real time for considered for
clinical trial or registry
•
All patients should be treated on a molecularly informed clinical trial.
•
Snap frozen tissue, paraffin embedded, blood and CSF should be collected on all patients